{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:35:14Z","timestamp":1789410914535,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00198-021-06268-9","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:31:54Z","timestamp":1642743114000},"page":"979-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cost-effectiveness analyses of denosumab for osteoporosis: a systematic review"],"prefix":"10.1007","volume":"33","author":[{"given":"Y.","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"6268_CR1","unstructured":"Kanis, J. (2007) Assessment of osteoporosis at the primary health-care level. WHO Scientific Group Technical Report. https:\/\/www.who.int\/chp\/topics\/rheumatic\/en\/index.html Accessed 26 July 2021."},{"issue":"3","key":"6268_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-018-00512-x","volume":"104","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int 104(3):235\u2013238. https:\/\/doi.org\/10.1007\/s00223-018-00512-x","journal-title":"Calcif Tissue Int"},{"key":"6268_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bone.2016.03.006","volume":"87","author":"EM Curtis","year":"2016","unstructured":"Curtis EM, van der Velde R, Moon RJ, van den Bergh JPW, Geusens P, de Vries F, van Staa TP, Cooper C, Harvey NC (2016) Epidemiology of fractures in the United Kingdom 1988\u20132012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 87:19\u201326. https:\/\/doi.org\/10.1016\/j.bone.2016.03.006","journal-title":"Bone"},{"issue":"5","key":"6268_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D (2013) Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 11(5):485\u2013497. https:\/\/doi.org\/10.1007\/s40258-013-0047-8","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"6268_CR5","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3969\/j.issn.1674-2591.2019.04.001","volume":"12","author":"Chinese Medical Association","year":"2019","unstructured":"Chinese Medical Association (2019) Epidemiological survey of osteoporosis in China and \u201cHealthy Bones\u201d special action results released. Chinese J Osteoporos Bone Miner Res 12(4):317\u2013318. https:\/\/doi.org\/10.3969\/j.issn.1674-2591.2019.04.001","journal-title":"Chinese J Osteoporos Bone Miner Res"},{"issue":"6937","key":"6268_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337\u2013342. https:\/\/doi.org\/10.1038\/nature01658","journal-title":"Nature"},{"issue":"10","key":"6268_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1060028018768808","volume":"52","author":"P Morizio","year":"2018","unstructured":"Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 52(10):1031\u20131041. https:\/\/doi.org\/10.1177\/1060028018768808","journal-title":"Ann Pharmacother"},{"issue":"Suppl 1","key":"6268_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3111\/13696998.2012.737393","volume":"15","author":"D Chau","year":"2012","unstructured":"Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R (2012) Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ 15(Suppl 1):3\u201314. https:\/\/doi.org\/10.3111\/13696998.2012.737393","journal-title":"J Med Econ"},{"key":"6268_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/CEOR.S78349","volume":"7","author":"J Darba","year":"2015","unstructured":"Darba J, Kaskens L, Vilela FS, Lothgren M (2015) Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clinicoecon Outcomes Res 7:105\u2013117. https:\/\/doi.org\/10.2147\/CEOR.S78349","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"6268_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jocd.2015.01.003","volume":"18","author":"CJ Yates","year":"2015","unstructured":"Yates CJ, Chauchard MA, Liew D, Bucknill A, Wark JD (2015) Bridging the osteoporosis treatment gap: performance and cost-effectiveness of a fracture liaison service. J Clin Densitom 18(2):150\u2013156. https:\/\/doi.org\/10.1016\/j.jocd.2015.01.003","journal-title":"J Clin Densitom"},{"issue":"5","key":"6268_CR11","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00198-017-3940-4","volume":"28","author":"T Mori","year":"2017","unstructured":"Mori T, Crandall CJ, Ganz DA (2017) Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan. Osteoporos Int 28(5):1733\u20131744. https:\/\/doi.org\/10.1007\/s00198-017-3940-4","journal-title":"Osteoporos Int"},{"issue":"1","key":"6268_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11657-018-0509-6","volume":"13","author":"T Yoshizawa","year":"2018","unstructured":"Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. Arch Osteoporos 13(1):94. https:\/\/doi.org\/10.1007\/s11657-018-0509-6","journal-title":"Arch Osteoporos"},{"issue":"10","key":"6268_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.18553\/jmcp.2019.25.10.1089","volume":"25","author":"QA Le","year":"2019","unstructured":"Le QA (2019) Patient-level modeling approach using discrete-event simulation: a cost-effectiveness study of current treatment guidelines for women with postmenopausal osteoporosis. J Manag Care Spec Pharm. 25(10):1089\u20131095. https:\/\/doi.org\/10.18553\/jmcp.2019.25.10.1089","journal-title":"J Manag Care Spec Pharm."},{"key":"6268_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-016-0060-5","volume":"14","author":"J Karnon","year":"2016","unstructured":"Karnon J, Shafie AS, Orji N, Usman SK (2016) What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. Cost Eff Resour Alloc 14:11. https:\/\/doi.org\/10.1186\/s12962-016-0060-5","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"6268_CR15","doi-asserted-by":"publisher","first-page":"238146831881884","DOI":"10.1177\/2381468318818843","volume":"4","author":"D Coyle","year":"2019","unstructured":"Coyle D (2019) Cost-effectiveness of pharmacological treatments for osteoporosis consistent with the revised economic evaluation guidelines for Canada. MDM Policy Pract 4(1):2381468318818843. https:\/\/doi.org\/10.1177\/2381468318818843","journal-title":"MDM Policy Pract"},{"issue":"7","key":"6268_CR16","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1080\/13696998.2020.1730381","volume":"23","author":"C Pongchaiyakul","year":"2020","unstructured":"Pongchaiyakul C, Nanagara R, Songpatanasilp T, Unnanuntana A (2020) Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand. J Med Econ 23(7):776\u2013785. https:\/\/doi.org\/10.1080\/13696998.2020.1730381","journal-title":"J Med Econ"},{"issue":"2","key":"6268_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N, Cornelissen D, Silverman S, Pinto D, Si L, Kremer I, Bours S, de Bot R, Boonen A, Evers S, van den Bergh J, Reginster J-Y, Hiligsmann M (2021) An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics 39(2):181\u2013209. https:\/\/doi.org\/10.1007\/s40273-020-00965-9","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"6268_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.afos.2020.05.006","volume":"6","author":"M Azharuddin","year":"2020","unstructured":"Azharuddin M, Adil M, Khan RA, Ghosh P, Kapur P, Sharma M (2020) Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: a quality appraisal. Osteoporos Sarcopenia 6(2):39\u201352. https:\/\/doi.org\/10.1016\/j.afos.2020.05.006","journal-title":"Osteoporos Sarcopenia"},{"issue":"3","key":"6268_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-014-0231-1","volume":"33","author":"M Hiligsmann","year":"2015","unstructured":"Hiligsmann M, Evers SM, Sedrine WB, Kanis JA, Ramaekers B, Reginster J-Y, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics 33(3):205\u2013224. https:\/\/doi.org\/10.1007\/s40273-014-0231-1","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"6268_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1586\/erp.12.76","volume":"13","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Boonen A, Dirksen CD, Sedrine WB, Reginster J-Y (2013) Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Rev Pharmacoecon Outcomes Res 13(1):19\u201328. https:\/\/doi.org\/10.1586\/erp.12.76","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"6268_CR21","first-page":"62","volume":"102","author":"S Chokchalermwong","year":"2019","unstructured":"Chokchalermwong S, Lochid-Amnuay S, Kapol N, Wiroonpochid E, Ongphiphadhanakul B (2019) Economic evaluation of drug treatment for fracture prevention in thai postmenopausal women with osteoporosis without fracture history. J Med Assoc Thailand 102(1):62\u201370","journal-title":"J Med Assoc Thailand"},{"issue":"2","key":"6268_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00223-016-0132-8","volume":"99","author":"A Marques","year":"2016","unstructured":"Marques A, Louren\u00e7o \u00d3, Orts\u00e4ter G, Borgstr\u00f6m F, Kanis JA, da Silva JA (2016) Cost-effectiveness of intervention thresholds for the treatment of osteoporosis based on FRAX(\u00ae) in Portugal. Calcif Tissue Int 99(2):131\u2013141. https:\/\/doi.org\/10.1007\/s00223-016-0132-8","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"6268_CR23","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson B, Str\u00f6m O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967\u2013982. https:\/\/doi.org\/10.1007\/s00198-010-1424-x","journal-title":"Osteoporos Int"},{"issue":"29","key":"6268_CR24","doi-asserted-by":"publisher","first-page":"v","DOI":"10.3310\/hta24290","volume":"24","author":"S Davis","year":"2020","unstructured":"Davis S, Simpson E, Hamilton J, James MMS, Rawdin A, Wong R, Goka E, Gittoes N, Selby P (2020) Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technol Assess 24(29):v\u2013313. https:\/\/doi.org\/10.3310\/hta24290","journal-title":"Health Technol Assess"},{"key":"6268_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bone.2013.11.002","volume":"59","author":"A Parthan","year":"2014","unstructured":"Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E (2014) Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone 59:105\u2013113. https:\/\/doi.org\/10.1016\/j.bone.2013.11.002","journal-title":"Bone"},{"key":"6268_CR26","doi-asserted-by":"publisher","first-page":"627631","DOI":"10.1155\/2015\/627631","volume":"2015","author":"S Silverman","year":"2015","unstructured":"Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E (2015) Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective. J Osteoporos 2015:627631. https:\/\/doi.org\/10.1155\/2015\/627631","journal-title":"J Osteoporos"},{"issue":"4","key":"6268_CR27","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00198-012-2115-6","volume":"24","author":"O Str\u00f6m","year":"2013","unstructured":"Str\u00f6m O, J\u00f6nsson B, Kanis JA (2013) Intervention thresholds for denosumab in the UK using a FRAX\u00ae-based cost-effectiveness analysis. Osteoporos Int 24(4):1491\u20131502. https:\/\/doi.org\/10.1007\/s00198-012-2115-6","journal-title":"Osteoporos Int"},{"issue":"3","key":"6268_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00198-020-05802-5","volume":"32","author":"M Hiligsmann","year":"2021","unstructured":"Hiligsmann M, Maggi S, Veronese N, Sartori L, Reginster J-Y (2021) Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy. Osteoporos Int. 32(3):595\u2013606. https:\/\/doi.org\/10.1007\/s00198-020-05802-5","journal-title":"Osteoporos Int."},{"issue":"Supplement 2","key":"6268_CR29","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jval.2018.07.613","volume":"21","author":"G Bae","year":"2018","unstructured":"Bae G, Kwon H, An J, Park J (2018) Cost-utility analysis of denosumab versus alendronate for postmenopausal osteoporosis in South Korea. Value Health 21(Supplement 2):S82. https:\/\/doi.org\/10.1016\/j.jval.2018.07.613","journal-title":"Value Health"},{"issue":"7","key":"6268_CR30","doi-asserted-by":"publisher","first-page":"A541","DOI":"10.1016\/j.jval.2016.09.1126","volume":"19","author":"J Garcia Perlaza","year":"2016","unstructured":"Garcia Perlaza J, Arocho R (2016) Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Colombia. Value Health 19(7):A541","journal-title":"Value Health"},{"issue":"3","key":"6268_CR31","doi-asserted-by":"publisher","first-page":"A47","DOI":"10.1016\/j.jval.2014.03.281","volume":"17","author":"Y Ding","year":"2014","unstructured":"Ding Y, Hay J (2014) Cost-effectiveness comparison of denosumab and zoledronic acid in the treatment of postmenopausal osteoporosis. Value Health 17(3):A47. https:\/\/doi.org\/10.1016\/j.jval.2014.03.281","journal-title":"Value Health"},{"issue":"3","key":"6268_CR32","doi-asserted-by":"publisher","first-page":"A223","DOI":"10.1016\/j.jval.2013.03.1130","volume":"16","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse MM, Agodoa I, Tao CY, Silverman SL, Orwoll E (2013) Is denosumab cost-effective compared to oral bisphosphonates for the treatment of male osteoporosis (MOP) in sweden? Value Health 16(3):A223. https:\/\/doi.org\/10.1016\/j.jval.2013.03.1130","journal-title":"Value Health"},{"key":"6268_CR33","unstructured":"Parthan, A., M. Kruse, I. Agodoa, S. Silverman, and E. Orwoll (2013) Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the us payer perspective. Journal of Bone and Mineral Research. 28(SUPPL. 1)."},{"issue":"3","key":"6268_CR34","doi-asserted-by":"publisher","first-page":"A225","DOI":"10.1016\/j.jval.2013.03.1141","volume":"16","author":"R Arocho","year":"2013","unstructured":"Arocho R, Rivera Hurtado R, Salinas Escudero G (2013) Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis (PMO) women in mexico at high risk of fractures and intolerant to oral bisphosphonates. Value Health 16(3):A225. https:\/\/doi.org\/10.1016\/j.jval.2013.03.1141","journal-title":"Value Health"},{"issue":"4","key":"6268_CR35","doi-asserted-by":"publisher","first-page":"A38","DOI":"10.1016\/j.jval.2012.03.215","volume":"15","author":"A Parthan","year":"2012","unstructured":"Parthan A, Deflin MM, Yurgin N, Huang J, Taylor DC (2012) Cost-effectiveness of denosumab versus oral bisphosphonates in the united states for post-menopausal osteoporosis (PMO). Value Health 15(4):A38. https:\/\/doi.org\/10.1016\/j.jval.2012.03.215","journal-title":"Value Health"},{"issue":"7","key":"6268_CR36","doi-asserted-by":"publisher","first-page":"A445","DOI":"10.1016\/j.jval.2012.08.1391","volume":"15","author":"J Lundkvist","year":"2012","unstructured":"Lundkvist J, Lothgren M, Badamgarav E, Freyschyss B (2012) Cost-effectiveness of denosumab for the treatment of elderly women with post-menopausal osteoporosis in Sweden. Value Health 15(7):A445\u2013A446. https:\/\/doi.org\/10.1016\/j.jval.2012.08.1391","journal-title":"Value Health"},{"issue":"4","key":"6268_CR37","doi-asserted-by":"publisher","first-page":"A38","DOI":"10.1016\/j.jval.2012.03.216","volume":"15","author":"Y Jiang","year":"2012","unstructured":"Jiang Y, Hay J (2012) The cost-effectiveness of denosumab for the prevention of osteoporotic fractures in the setting of the United States. Value Health 15(4):A38. https:\/\/doi.org\/10.1016\/j.jval.2012.03.216","journal-title":"Value Health"},{"issue":"7","key":"6268_CR38","doi-asserted-by":"publisher","first-page":"A673","DOI":"10.1016\/j.jval.2012.08.416","volume":"15","author":"WL Chang","year":"2012","unstructured":"Chang WL, Ling YL, Huang KC, Tang CH (2012) An economic evaluation of denosumab in the treatment of postmenopausal osteoporosis in a Taiwanese setting. Value Health 15(7):A673. https:\/\/doi.org\/10.1016\/j.jval.2012.08.416","journal-title":"Value Health"},{"issue":"7","key":"6268_CR39","doi-asserted-by":"publisher","first-page":"A446","DOI":"10.1016\/j.jval.2012.08.1396","volume":"15","author":"EG Barbosa","year":"2012","unstructured":"Barbosa EG, Machado M, Araujo GTBD, Etto H, Fonseca M, Olimpio A (2012) Cost-effectiveness of denosumab in preventing osteoporotic fractures in postmenopausal women from the private health care setting perspective in Brazil. Value Health 15(7):A446\u2013A447. https:\/\/doi.org\/10.1016\/j.jval.2012.08.1396","journal-title":"Value Health"},{"issue":"7","key":"6268_CR40","doi-asserted-by":"publisher","first-page":"A310","DOI":"10.1016\/j.jval.2011.08.430","volume":"14","author":"A Davies","year":"2011","unstructured":"Davies A, Compston J, Ferguson S, McClosky E, Shearer A, Taylor A (2011) Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Scotland. Value Health 14(7):A310. https:\/\/doi.org\/10.1016\/j.jval.2011.08.430","journal-title":"Value Health"},{"issue":"7","key":"6268_CR41","doi-asserted-by":"publisher","first-page":"A311","DOI":"10.1016\/j.jval.2011.08.434","volume":"14","author":"J Darba","year":"2011","unstructured":"Darba J, Kaskens L, Sorio F (2011) Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Value Health 14(7):A311. https:\/\/doi.org\/10.1016\/j.jval.2011.08.434","journal-title":"Value Health"},{"issue":"3","key":"6268_CR42","doi-asserted-by":"publisher","first-page":"A128","DOI":"10.1016\/j.jval.2011.02.715","volume":"14","author":"J Cristino","year":"2011","unstructured":"Cristino J, Canhao H, Perelman J, Santos C, Pereira J (2011) Cost-utility analysis of denosumab versus standard care in the treatment of post-menopausal osteoporosis in Portugal. Value Health 14(3):A128","journal-title":"Value Health"},{"issue":"3","key":"6268_CR43","doi-asserted-by":"publisher","first-page":"A129","DOI":"10.1016\/j.jval.2011.02.719","volume":"14","author":"AC Beaubrun","year":"2011","unstructured":"Beaubrun AC, Daugherty JB (2011) Cost-utility analysis of denosumab versus raloxifene for treating osteoporosis in post-menopausal women in the United States. Value Health 14(3):A129","journal-title":"Value Health"},{"issue":"7","key":"6268_CR44","doi-asserted-by":"publisher","first-page":"A308","DOI":"10.1016\/j.jval.2011.08.421","volume":"14","author":"K Athanasakis","year":"2011","unstructured":"Athanasakis K, Karampli E, Hollandezos M, Papagiannopoulou V, Badamgarav E, Intorcia M, Kyriopoulos J (2011) A cost-effectiveness analysis of denosumab for the treatment of post-menopausal osteoporosis in Greece. Value Health 14(7):A308. https:\/\/doi.org\/10.1016\/j.jval.2011.08.421","journal-title":"Value Health"},{"key":"6268_CR45","doi-asserted-by":"publisher","unstructured":"Parthan, A., M. Deflin, N. Yurgin, J. Huang, P.R. Ho, A. Wang, and D. Taylor (2012) Cost-effectiveness of denosumab versus zoledronic acid in a population 75 years or older in the us. Journal of Bone and Mineral Research. 27(SUPPL. 1). https:\/\/doi.org\/10.1007\/s00198-013-2312-y.","DOI":"10.1007\/s00198-013-2312-y"},{"key":"6268_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00198-008-0644-9","volume":"20","author":"O Strom","year":"2009","unstructured":"Strom O, Macarios D, Badamgarav E, Borgstrom F, Jonsson B, Tosteson A, Kanis J (2009) Cost-effectiveness model for denosumab incorporating Frax (R) and adherence in a UK setting. Osteoporos Int 20:20\u201320","journal-title":"Osteoporos Int"},{"issue":"11","key":"6268_CR47","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2165\/11589310-000000000-00000","volume":"29","author":"G Scotland","year":"2011","unstructured":"Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R (2011) Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics 29(11):951\u2013961. https:\/\/doi.org\/10.2165\/11589310-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"6268_CR48","first-page":"S137","volume":"24","author":"B Stolshek","year":"2013","unstructured":"Stolshek B, Kruse M, Yurgin N, Huang J, Ho PR, Wang A, Parthan A, Taylor D (2013) Cost-effectiveness of denosumab vs. zoledronic acid in a population 75 years or older in the US. Osteoporos Int 24(1):S137\u2013S138","journal-title":"Osteoporos Int"},{"issue":"10","key":"6268_CR49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/11539980-000000000-00000","volume":"29","author":"M Hiligsmann","year":"2011","unstructured":"Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29(10):895\u2013911. https:\/\/doi.org\/10.2165\/11539980-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"6268_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bone.2010.03.009","volume":"47","author":"M Hiligsmann","year":"2010","unstructured":"Hiligsmann M, Reginster JY (2010) Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47(1):34\u201340. https:\/\/doi.org\/10.1016\/j.bone.2010.03.009","journal-title":"Bone"},{"key":"6268_CR51","doi-asserted-by":"publisher","unstructured":"de Waure, C., M.L. Specchia, C. Cadeddu, S. Capizzi, S. Capri, M.L. Di Pietro, M.A. Veneziano, M.R. Gualano, F. Kheiraoui, T. Giuseppe La, N. Nicolotti, A. Sferrazza, and W. Ricciardi (2014) The prevention of postmenopausal osteoporotic fractures: results of the health technology assessment of a new antiosteoporotic drug. Biomed Res Int. 2014https:\/\/doi.org\/10.1155\/2014\/975927","DOI":"10.1155\/2014\/975927"},{"issue":"3","key":"6268_CR52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1586\/14737167.2016.1165608","volume":"16","author":"JJ Caro","year":"2016","unstructured":"Caro JJ, M\u00f6ller J (2016) Advantages and disadvantages of discrete-event simulation for health economic analyses. Expert Rev Pharmacoecon Outcomes Res 16(3):327\u2013329. https:\/\/doi.org\/10.1586\/14737167.2016.1165608","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"6268_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00198-018-4744-x","volume":"30","author":"M Hiligsmann","year":"2019","unstructured":"Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, Al-Daghri N, Bruy\u00e8re O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S (2019) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts\u2019 consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporos Int 30(1):45\u201357. https:\/\/doi.org\/10.1007\/s00198-018-4744-x","journal-title":"Osteoporos Int"},{"issue":"4","key":"6268_CR54","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11530530-000000000-00000","volume":"28","author":"RL Fleurence","year":"2010","unstructured":"Fleurence RL, Spackman DE, Hollenbeak C (2010) Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics 28(4):295\u2013306. https:\/\/doi.org\/10.2165\/11530530-000000000-00000","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"6268_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11657-021-00956-z","volume":"16","author":"T Mori","year":"2021","unstructured":"Mori T, Crandall CJ, Fujii T, Ganz DA (2021) Cost-effectiveness of zoledronic acid compared with sequential denosumab\/alendronate for older osteoporotic women in Japan. Arch Osteoporos 16(1):113. https:\/\/doi.org\/10.1007\/s11657-021-00956-z","journal-title":"Arch Osteoporos"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06268-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06268-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06268-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T17:05:23Z","timestamp":1649955923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06268-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6268"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06268-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}